Back to case studies
Case Study
A drug-free and medically approved at-home depression treatment
April 9, 2023

Background and Context

Founded in 2016 by clinical psychologist Daniel Månsson, and neuroscientist Erik Rehn, the Malmö-based Flow Neuroscience aims to fill the treatment gap between medication and therapy with the Flow headset solution, which is a drug-free and medically approved, at-home depression treatment. The headset uses transcranial direct current stimulation (tDCS), a pain-free and non-invasive technique that activates neural networks through gentle currents to reduce depression.

Q&A with Founder 

Flow Neuroscience co-founders Daniel Mansson and Erik Rehn with CEO Erin Lee

Why did you find Flow Neuroscience?

We founded Flow to, ambitiously, solve the problem of depression.

How did HAX progress your startup?

HAX was instrumental to Flow’s journey. The program provided the perfect environment to focus on the development of the hardware component, the most vital part of the product. It was a free-zone to work hard together with other motivated individuals and engineers of HAX. 

How did your recent Series A come together? What were other investors excited about?

The recent Series A was led by Khosla Ventures, Swiss Health Ventures and Zuehlke Ventures. Khosla Ventures has been with us since the seed round and has been there when it matters most. Swiss Health Ventures came in as a European counterpart with a strong background in healthcare as the venture arm of the largest Healthcare Insurer in Switzerland.

We believe that tDCS can become the first line of treatment for patients suffering from moderate-severe depression.

How are you thinking about your healthcare impact?

With the clinical results we are seeing right now combined with a strong uptick in clinics adopting the treatment, the possibilities for this treatment are very big. We believe that tDCS can become the first line of treatment for patients suffering from moderate-severe depression.

With the clinical results we are seeing right now combined with a strong uptick in clinics adopting the treatment, the possibilities for  this treatment are very big. We believe that tDCS can become the first line of treatment for patients suffering from moderate-severe depression.